(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 February 2025 (27.02.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/042865 A1

(51) International Patent Classification:
*C07K 16/30* (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2024/042988

(22) International Filing Date:
20 August 2024 (20.08.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/533,824 21 August 2023 (21.08.2023) US

(71) Applicants: **AMGEN RESEARCH (MUNICH) GMBH** [DE/DE]; Staffelseestrasse 2, 81477 Munich (DE). **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US).

(72) Inventors: **STIEGLMAIER, Julia**; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). **KISCHEL, Roman**; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). **KOUROS-MEHR, Hosein**; c/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks, CA 91320-1799 (US).

(74) Agent: **BRASHEAR, Jeanne, M.** et al.; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

WO 2025/042865 A1

(54) **Title:** METHODS FOR TREATING PROSTATE CANCER WITH BISPECIFIC ANTIBODIES BINDING STEAP1XCD3

FIG.1




(57) **Abstract:** The present disclosure provides methods of treating prostate cancer patients with an anti- STEAP1 antigen binding protein such as xaluritamig either as a monotherapy or in combination with another therapeutic agent.

*[Continued on next page]*

**Published:**

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*